These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32283176)

  • 1. Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals.
    Wagner JL; Rhodes NJ; Scheetz MH; Bosso JA; Goff DA; Rybak MJ; Davis SL;
    Int J Antimicrob Agents; 2020 Jun; 55(6):105970. PubMed ID: 32283176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
    Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB
    J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Penicillin Allergy on Empirical Carbapenem Use in Gram-Negative Bloodstream Infections: An Antimicrobial Stewardship Opportunity.
    Al-Hasan MN; Acker EC; Kohn JE; Bookstaver PB; Justo JA
    Pharmacotherapy; 2018 Jan; 38(1):42-50. PubMed ID: 29105102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a Carbapenem Antimicrobial Stewardship Program on Patient Outcomes.
    Seah VXF; Ong RYL; Lim ASY; Chong CY; Tan NWH; Thoon KC
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparing carbapenem usage.
    Wilson APR
    J Antimicrob Chemother; 2017 Sep; 72(9):2410-2417. PubMed ID: 28637307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained pediatric antimicrobial stewardship program with consultation to infectious diseases reduced carbapenem resistance and infection-related mortality.
    Horikoshi Y; Suwa J; Higuchi H; Kaneko T; Furuichi M; Aizawa Y; Fukuoka K; Okazaki K; Ito K; Shoji T
    Int J Infect Dis; 2017 Nov; 64():69-73. PubMed ID: 28941633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing carbapenem-resistance testing algorithms for Enterobacteriales and Pseudomonas aeruginosa: diagnostic and antimicrobial stewardship with timely infection prevention.
    Vega AD; Jimenez A; Rosello G; Claeys KC; Martinez OV; De Pascale B; Perez-Cardona A; Abbo L
    Diagn Microbiol Infect Dis; 2020 Aug; 97(4):115069. PubMed ID: 32559587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals.
    Papst L; Beović B; Pulcini C; Durante-Mangoni E; Rodríguez-Baño J; Kaye KS; Daikos GL; Raka L; Paul M;
    Clin Microbiol Infect; 2018 Oct; 24(10):1070-1076. PubMed ID: 29410094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic consumption versus the prevalence of carbapenem-resistant Gram-negative bacteria at a tertiary hospital in China from 2011 to 2017.
    Zhang D; Hu S; Sun J; Zhang L; Dong H; Feng W; Lei J; Dong Y
    J Infect Public Health; 2019; 12(2):195-199. PubMed ID: 30385238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of antimicrobial stewardship program on antimicrobial usage and detection rate of multidrug-resistant gram-negative bacteria].
    Xu YL; Hu LM; Xie ZZ; Dong YW; Dong L
    Zhonghua Er Ke Za Zhi; 2019 Jul; 57(7):553-558. PubMed ID: 31269557
    [No Abstract]   [Full Text] [Related]  

  • 11. Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.
    Walker MK; Diao G; Warner S; Babiker A; Neupane M; Strich JR; Yek C; Kadri SS;
    Lancet Infect Dis; 2024 Aug; 24(8):856-867. PubMed ID: 38679036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program.
    Sadyrbaeva-Dolgova S; Aznarte-Padial P; Jimenez-Morales A; Expósito-Ruiz M; Calleja-Hernández MÁ; Hidalgo-Tenorio C
    J Infect Public Health; 2020 Apr; 13(4):558-563. PubMed ID: 31685404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of carbapenem-resistant Gram-negative infections globally.
    Brink AJ
    Curr Opin Infect Dis; 2019 Dec; 32(6):609-616. PubMed ID: 31567571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing health care-associated infections: A multicenter comparison.
    Lai CC; Shi ZY; Chen YH; Wang FD
    J Microbiol Immunol Infect; 2016 Feb; 49(1):74-82. PubMed ID: 26586483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014.
    Yang P; Chen Y; Jiang S; Shen P; Lu X; Xiao Y
    Antimicrob Resist Infect Control; 2018; 7():137. PubMed ID: 30479750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Carbapenem Use Before and After Implementation of an Antimicrobial Stewardship-Led Carbapenem-Sparing Strategy in a Lebanese Tertiary Hospital: A Retrospective Study.
    El Masri M; Haddad N; Saad T; Rizk NA; Zakhour R; Kanj SS; Zeenny RM
    Front Cell Infect Microbiol; 2022; 12():729491. PubMed ID: 35402313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the multidisciplinary antimicrobial stewardship team intervention focusing on carbapenem de-escalation: A single-centre and interrupted time series analysis.
    Suzuki A; Maeda M; Yokoe T; Hashiguchi M; Togashi M; Ishino K
    Int J Clin Pract; 2021 Mar; 75(3):e13693. PubMed ID: 32893441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.
    Ting SW; Lee CH; Liu JW
    J Microbiol Immunol Infect; 2018 Oct; 51(5):621-628. PubMed ID: 28732563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
    Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
    Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system.
    Ahmad F; Pogue JM; Marchaim D; Chopra T; Bheemreddy S; Lee J; Mudegowdra NS; Chaudhry A; Kaye KS
    J Infect Public Health; 2014 Feb; 7(1):50-3. PubMed ID: 24210246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.